Large-Scale Trial of Cellular-Based Accident Prevention
14 July, 2019
The experiment will involve approximately 30,000 participants. Eye-Net is a cellular-based vehicle-to-everything (V2X) accident prevention solution designed to protect the road users in real time
Foresight Autonomous Holdings (NASDAQ: FRSX) announced that its wholly owned subsidiary, Eye-Net Mobile will conduct in Israel a large-scale trial of its Eye-Net cellular-based accident prevention solution for the first time. This trial marks the result of two-and-a-half years of development, and represents a milestone for the company as it transitions from technology to product.
Thousands of users are expected to participate in the five-day trial, which will take place from July 24th until July 29th, 2019. The trial is open to the general public and is limited to the first 30,000 enrolled participants. Eye-Net is a cellular-based vehicle-to-everything (V2X) accident prevention solution designed to protect the most vulnerable road users in real time—including pedestrians, cyclists, scooter drivers and car drivers—by providing collision alerts when the road users have no direct line of sight.
It is deployed on smartphones and cloud-based servers, connected by the existing cellular networks. The basic concept is simple: The phone is aware of its location and constantly transmits it to Eye-Net servers, who send the location of other devices in the vicinity to each device, effectively making each device aware of the road users around it. The Eye-Net application is constantly searching for potential collisions, and once an oncoming collision is detected, immediate visual and audio alerts are sent out to all users involved.
Universal Transportation Solutions Ltd. (Avis Israel franchisee) and the Eldan group, two leading global and local car rental and leasing groups; Trade Mobile, a leading trade-in company of leading car importers in Israel; as well as Shagrir Group Vehicle Services Ltd., a leading Israeli provider of towing and roadside assistance services, have expressed willingness to participate in the trial.